← Back to Calendar

Geron Corporation Q1 2026 Earnings

Geron Corporation · $GERN
Standard Review Earnings
Catalyst Date
May 7, 2026
Time Remaining
24 days
Review Type
Standard (10 mo)

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$1.67 +28.46%
+$0.37 today
Day: $1.66 – $1.78
Market Cap
N/A
Shares out: 640.90M
Float: 510.78M
52-Week Range
$1.04
$2.01
Current price is at 65% of 52-week range
Avg Volume
18.04M
Beta
0.67
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $GERN catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q1 2026 earnings + RYTELO commercial + sBLA update

Key Notes

Q1 2026 earnings expected ~May 2026. Key updates: RYTELO Q1 revenue trajectory vs $220M–$240M guidance; MDS sBLA PDUFA April 15 outcome expected to be known; IMpactMF Phase 3 OS data update.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar